Sarepta Therapeutics to Present Company Overview at the Goldman Sachs 38th Annual Global Healthcare Conference
May 30, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2017 17:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
April 27, 2017 16:01 ET
|
Sarepta Therapeutics
-- First quarter 2017 EXONDYS 51 total net revenues of $16.3 million -- -- Company anticipates net revenues for the year will exceed $95 million -- CAMBRIDGE, Mass., April 27, 2017 (GLOBE...
Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017
April 17, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2017 17:00 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer
April 03, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2017 18:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board
March 30, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference
March 17, 2017 08:30 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique...
Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference
March 02, 2017 18:00 ET
|
Sarepta Therapeutics
CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is...